NM_000546.6:c.572_574delCTC
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PM4_SupportingPP5
The NM_000546.6(TP53):c.572_574delCTC(p.Pro191del) variant causes a disruptive inframe deletion change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000546.6 disruptive_inframe_deletion
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Li-Fraumeni syndrome Pathogenic:1
This variant, c.572_574del, results in the deletion of 1 amino acid(s) of the TP53 protein (p.Pro191del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with clinical features of Li-Fraumeni syndrome (PMID: 33245408; external communication, internal data). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects TP53 function (PMID: 33116240). For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
Published functional studies demonstrate a damaging effect: loss of transactivation activity (Monti 2020); Not observed in large population cohorts (Lek 2016); In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 33116240, 28522256, 30185652, 29805648, 29489027, 30041611, 27407063, 25313908, 22983585, 21483000, 26425688, 26205736, 27045317, 27586204, 11454518, 31317311) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.572_574delCTC variant (also known as p.P191del) is located in coding exon 5 of the TP53 gene. This variant results from an in-frame CTC deletion at nucleotide positions 572 to 574. This results in the in-frame deletion of a proline at codon 191. This alteration has been reported in an individual meeting Chompret criteria (Grill S et al. Arch Gynecol Obstet, 2020 Nov) and has also been observed in at least one individual with a personal and/or family history that is consistent with TP53-related disease (Ambry internal data, personal communication). This alteration has also been reported in the tumor of an individual with adrenocortical carcinoma (Barzon L et al. Eur. J. Endocrinol., 2001 Aug;145:207-12). This variant is in the DNA binding domain of the TP53 protein and is reported to have partially functional transactivation in yeast and human cell assays (Monti P et al. Sci Rep, 2020 10;10:18427). Based on internal structural assessment, this alteration results in disruption of the DNA-binding domain (Ambry internal data). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Hereditary breast ovarian cancer syndrome Uncertain:1
According to the ClinGen ACMG TP53 v1.4.0 criteria we chose these criteria: PS4 (supporting pathogenic): Multiple Individuals meeting chompret criteria, PM2 (supporting pathogenic): not in gnomAD -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at